<DOC>
	<DOCNO>NCT00484874</DOCNO>
	<brief_summary>The purpose study find high safe dose Iodine-131 Tositumomab ( Bexxar® ) give patient relapsed/refractory Hodgkin 's lymphoma , side effect patient get take Bexxar® Bexxar® effective treat relapsed/refractory Hodgkin 's lymphoma . Bexxar® work deliver dos radiation cancer cell .</brief_summary>
	<brief_title>Safety Efficacy Study I-131 Tositumomab Patients With Relapsed/Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>One third patient Hodgkin 's lymphoma ( HL ) respond disease come back first therapy . These patient often receive high-dose chemotherapy blood marrow transplant . Despite high response rate transplant , significant number , 26-65 % , patient disease come back . After transplant , therapy option limit alternative therapy patient HL relapse post-transplant ineligible transplant need . Based recent study HL develop good result patient study evaluate use unlabeled anti-CD20 antibody Rituximab HL , think radioimmunotherapy ( RIT ) I-131 Tositumomab ( Bexxar® ) effective alternative therapy patient relapsed/refractory HL post ineligible transplant . The rationale use RIT cancer radiolabeled monoclonal antibody specifically target irradiate tumor cell normal tissue . The specific tumor target RIT theoretically allow high dos radiation deliver tumor compare external beam radiation effect radiation normal tissue less RIT . Iodine-131 Tositumomab ( Bexxar® ) approve FDA another type lymphoma 2003 . The antibody ( Tositumomab ) recognize attache protein lymphoma cell kill cell . The radioisotope ( I-131 ) help antibody kill cell well . Iodine-131 Tositumomab ( Bexxar® ) give vein arm . Iodine-131 Tositumomab ( Bexxar® ) give outpatient setting .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Biopsyproven Hodgkin 's lymphoma relapse refractory patient previously transplant ineligible transplant All stag histologic subtypes Hodgkin 's lymphoma Malignant cell may CD20+ CD20 May previously either nonmyeloablative myeloablative allogeneic autologous stem cell transplant If prior history great 1 transplant , eligible entry criterion meet No upper limit amount prior chemotherapy Must least 4 week recent chemotherapy radiation therapy , 6 week last regimen include BCNU , mitomycin Age 18 great Karnofsky performance status ≥ 60 Organ marrow function within 4 week registration protocol define : Leukocytes &gt; 2,000/mm3 Absolute neutrophil count &gt; 1,000/ mm3 Platelets &gt; 75,000/ mm3 Hemoglobin &gt; 7 g/dL Creatinine &lt; 2.5 mg/dL Less 25 % bone marrow involvement Hodgkin 's lymphoma within 4 week registration protocol If female , pregnant breast feed Ability understand willingness sign write informed consent document At least one measurable target lesion , measure 1.5 cm least one dimension standard CT image FDG avid PET/CT . 2year expect survival disease Receiving investigational agent time Hypocellular bone marrow ( less equal 10 % cellularity ) mark decrease one ( ) hematopoietic precursor within 4 week registration protocol Inability follow basic radiation safety precaution Active infection require intravenous antibiotic resolution infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Bexxar</keyword>
	<keyword>I-131 Tositumomab</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Nuclear Medicine</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Radiolabeled</keyword>
</DOC>